Puma Biotechnology Showcases Pipeline Progress and NERLYNX Commercial Updates in New Corporate Presentation

Reuters

2025/11/18

Puma Biotechnology Showcases Pipeline Progress and NERLYNX Commercial Updates in New Corporate Presentation

Puma Biotechnology Inc. presented updates on the commercialization of NERLYNX®, including recent performance metrics and distribution network information. The company reported net revenue of $51.9 million in Q3 2025, reflecting an approximately 8% decrease compared to Q3 2024, but a 6% increase from Q2 2025. Inventory changes amounted to $3.1 million in Q3 2025, up from $0.7 million in Q3 2024 and -$1.3 million in Q2 2025. The number of bottles distributed in Q3 2025 was 2,723, compared to 2,949 in Q3 2024 and 2,608 in Q2 2025. The percentage of patients starting NERLYNX® at a reduced dose continued to fluctuate, with the latest figures indicating varying adoption rates. The company also provided a regional update on regulatory approvals and commercial launches, highlighting recent progress in Australia, Southeast Asia, and other markets. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Puma Biotechnology Inc. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2584677769"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2584677769\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2584677769?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-18 06:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584677769","market":"nz","top_or_hot":-1,"title":"Puma Biotechnology Showcases Pipeline Progress and NERLYNX Commercial Updates in New Corporate Presentation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Puma Biotechnology Showcases Pipeline Progress and NERLYNX Commercial Updates in New Corporate Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PBYI\">Puma Biotechnology Inc</a>. presented updates on the commercialization of NERLYNX®, including recent performance metrics and distribution network information. The company reported net revenue of $51.9 million in Q3 2025, reflecting an approximately 8% decrease compared to Q3 2024, but a 6% increase from <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2025. Inventory changes amounted to $3.1 million in Q3 2025, up from $0.7 million in Q3 2024 and -$1.3 million in Q2 2025. The number of bottles distributed in Q3 2025 was 2,723, compared to 2,949 in Q3 2024 and 2,608 in Q2 2025. The percentage of patients starting NERLYNX® at a reduced dose continued to fluctuate, with the latest figures indicating varying adoption rates. The company also provided a regional update on regulatory approvals and commercial launches, highlighting recent progress in Australia, Southeast Asia, and other markets. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Puma Biotechnology Inc. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Puma Biotechnology Showcases Pipeline Progress and NERLYNX Commercial Updates in New Corporate Presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPuma Biotechnology Showcases Pipeline Progress and NERLYNX Commercial Updates in New Corporate Presentation\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-18 06:33</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Puma Biotechnology Showcases Pipeline Progress and NERLYNX Commercial Updates in New Corporate Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PBYI\">Puma Biotechnology Inc</a>. presented updates on the commercialization of NERLYNX®, including recent performance metrics and distribution network information. The company reported net revenue of $51.9 million in Q3 2025, reflecting an approximately 8% decrease compared to Q3 2024, but a 6% increase from <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2025. Inventory changes amounted to $3.1 million in Q3 2025, up from $0.7 million in Q3 2024 and -$1.3 million in Q2 2025. The number of bottles distributed in Q3 2025 was 2,723, compared to 2,949 in Q3 2024 and 2,608 in Q2 2025. The percentage of patients starting NERLYNX® at a reduced dose continued to fluctuate, with the latest figures indicating varying adoption rates. The company also provided a regional update on regulatory approvals and commercial launches, highlighting recent progress in Australia, Southeast Asia, and other markets. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Puma Biotechnology Inc. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL4H6Yz:1","article_id":"2584677769","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584677769","pubTimestamp":1763418812,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Puma Biotechnology Inc. presented updates on the commercialization of NERLYNX, including recent performance metrics and distribution network information. The company reported net revenue of $51.9 million in Q3 2025, reflecting an approximately 8% decrease compared to Q3 2024, but a 6% increase from Q2 2025. Inventory changes amounted to $3.1 million in Q3 2025, up from $0.7 million in Q3 2024 and -$1.3 million in Q2 2025. The number of bottles distributed in Q3 2025 was 2,723, compared to 2,949 in Q3 2024 and 2,608 in Q2 2025. The percentage of patients starting NERLYNX at a reduced dose continued to fluctuate, with the latest figures indicating varying adoption rates. The company also provided a regional update on regulatory approvals and commercial launches, highlighting recent progress in Australia, Southeast Asia, and other markets. You can access the full presentation through the link below.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","PBYI":"Puma Biotechnology Inc"},"translate_title":"Puma Biotechnology在新的公司演示中展示了管道进展和NERLYNX商业更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PBYI":0.9},"content_text":"Puma Biotechnology Showcases Pipeline Progress and NERLYNX Commercial Updates in New Corporate Presentation\n    \n\nPuma Biotechnology Inc. presented updates on the commercialization of NERLYNX®, including recent performance metrics and distribution network information. The company reported net revenue of $51.9 million in Q3 2025, reflecting an approximately 8% decrease compared to Q3 2024, but a 6% increase from Q2 2025. Inventory changes amounted to $3.1 million in Q3 2025, up from $0.7 million in Q3 2024 and -$1.3 million in Q2 2025. The number of bottles distributed in Q3 2025 was 2,723, compared to 2,949 in Q3 2024 and 2,608 in Q2 2025. The percentage of patients starting NERLYNX® at a reduced dose continued to fluctuate, with the latest figures indicating varying adoption rates. The company also provided a regional update on regulatory approvals and commercial launches, highlighting recent progress in Australia, Southeast Asia, and other markets. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Puma Biotechnology Inc. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}